Introduction
Hematopoietic stem cell (HSC) products are routinely cultured for sterility, mostly to comply with regulatory requirements. 1, 2 Although bacterial contamination of these products seems to be a rare event, few studies have evaluated the frequency of cell graft contamination, particularly in regard to the extent of cell manipulation. [3] [4] [5] In addition, little is known about the clinical consequences of infusing contaminated grafts in severely immunocompromised neutropenic recipients. 6, 7 In 1996, Webb et al. 4 followed 73 recipients of contaminated HSC products for 48 h, and reported that 13.7% developed fever or positive blood cultures. However this short observation period postinfusion could have underestimated the true incidence of complications following infusions of contaminated grafts in highly vulnerable recipients. Indeed, when cell grafts are contaminated, the infectious inoculum is most likely very low and the contaminating organisms usually consist of less virulent skin contaminant bacteria. 8 Thus, even in transplant patients who are at high risk for infections, complications following infusion of contaminated HSCs could occur beyond the first 48 h after the infusion of contaminated cell grafts.
To determine the incidence of cell graft contamination according to manipulation levels, we measured the incidence of positive sterility cultures in cell graft products that were either administered fresh, frozen or after a purging procedure at our center over a 15-year period. In addition, we evaluated the clinical consequences of infusing such contaminated grafts. To ensure that delayed infectious events would not be overlooked, recipients were also assessed for fever and septicemia over a period of 14 days after infusion of the graft.
Patients and methods

Patient characteristics
Sterility cultures of 1502 bone marrow and peripheral blood cell grafts (978 autologous and 524 allogeneic) processed at the Cellular Therapy Laboratory of the Hopital Maisonneuve-Rosemont were reviewed. These grafts corresponded to 938 patients undergoing stem cell transplantation between June 1990 and July 2005. Patient and graft characteristics are described in Table 1 . Sterility control cultures were performed routinely on all procurement bags and at the pre-cryopreservation phase for allogeneic (when appropriate) and autologous grafts. Treated grafts (211; 14%) had additional cultures at each step of the cell processing. Cell graft treatment implied purging of autologous malignant cells using immunotoxin conjugates (anti-My9-bR, anti-B4-bR: ImmunoGen Inc., Cambridge, MA, USA) 9, 10 and photodynamic therapy (dibromorhodamine: Celmed BioSciences Inc., Montreal, QC, Canada and benzoporphyrin monoacid-A: QLT Inc., Vancouver, BC, Canada), [11] [12] [13] and elimination of allogeneic T lymphocytes using immunomagnetic microspheres (anti-CD34 beads, Miltenyi Biotec Inc., Auburn, CA, USA) 14, 15 and alloreactive T-cell populations (dibromorhodamine photodynamic processing). 16, 17 Sterility cultures Surveillance cultures for bacterial contamination were performed by inoculating 0.15 ml of the cell graft into 5 ml of chopped (cooked) meat in peptone broth obtained from commercial source (Oxoid Ltd, Basingstoke, Hampshire, England). Inoculated broths were incubated at 371C and examined daily for up to 7 days. Visually turbid broths were subcultured on blood and MacConkey agars. Grafts with at least one subculture plate positivity were considered contaminated.
Clinical outcome
Medical records of recipients of contaminated grafts were reviewed to determine the clinical consequences of infusing contaminated grafts. Febrile neutropenia episodes, documented bacteremia and other clinically or microbiologically documented infections within 14 days following the infusion of the contaminated grafts were retrieved.
Statistical analysis
A Yates-corrected chi-squared test was used for the analysis of proportions.
Results
Graft contamination prevalence and isolated microorganisms Among the 1502 cell collections during the 15-year period, routine sterility culture identified 15 (1.0%) positive grafts ( Table 2 ). Bone marrow grafts were contaminated in two instances, the other 13 being peripheral blood grafts. A total of 33 samples were obtained for these 15 patients, and 20 samples (64%) demonstrated bacterial contamination. The microorganisms recovered were coagulase negative Staphylococcus sp (CNS) (eight), Enterococcus sp (two), Streptococcus viridans (one), Group G -hemolytic Streptococcus (one), Diphtheroids (one), Sphingomonas paucibilis (one), Bacillus sp (one) and Burkholderia sp (one).
Bacterial contamination was not significantly more frequent in autologous (1.1%) than in allogeneic (0.8%) grafts, where cell manipulations were much more limited as most grafts did not have to undergo freezing (P ¼ 0.7). This difference also failed to attain statistical significance when considering the proportion of patients receiving contaminated grafts. In addition, there was no difference in contamination between samples originating from bone marrow or peripheral blood (data not shown), and administered fresh or frozen. Interestingly, grafts undergoing additional cell treatment in the form of purging of malignant cells from autologous grafts and T-cell populations from allogeneic collections demonstrated a frequency of contamination (0.5%) similar to that of untreated grafts (1.1%; P ¼ 0.7). No correlation was observed between the graft contamination rates and the nature of the patients' underlying disease and risk status (data not shown), despite theoretical considerations that procurement of cells from patients with low or impaired marrow recovery owing to previous exposure to intensive or repeated chemotherapy protocols is more problematic.
Although 13 grafts had two or more samples evaluated for bacterial contamination, the majority (nine of the 13 (Table 3) .
Patient outcome
Of the 15 patients with contaminated grafts, symptoms of infection at the time of collection were present in only one patient (patient 4). This patient had a documented catheter sepsis owing to Group G b-hemolytic Streptococcus that resolved upon removal of the catheter and treatment with antibiotics. The graft culture was positive for the same bacteria, and this cell collection was therefore discarded. Another HSC mobilization was performed and the patient received uneventfully the second autologous stem cell collection a few months later. One graft was contaminated with S. paucibilis at both collection and pre-cryopreservation phases. This graft was also discarded. Overall, 13 patients were transplanted with grafts demonstrating positive sterility cultures (Table 3) . At the time of their transplantation, all 13 patients were on oral trimethoprim-sulfamethoxazole that was routinely administered to all HSC transplant patients as bacterial prophylaxis. In only five patients, this antibiotic was changed to a specific pre-emptive regimen, following the attending physician's assessment, in order to potentially limit the clinical consequences of infusing a contaminated graft. Vancomycin was administered to four patients, and a third-generation cephalosporin to one patient.
Fever (defined as temperature of 38.31C or greater) developed in 9/13 (69%) patients between the first and tenth day (median 5 days) post-infusion of the contaminated graft. Fever was associated with bacteremia in two patients. One of these two patients (patient 1) had S. epidermidis in one of the two blood cultures drawn from his Broviac catheter on day þ 5. Semiquantitative culture from the removed Broviac catheter tip showed three colonies of CNS. This patient's intermediate and pre-freezing samples grafts were also contaminated with CNS. Although comparative epidemiological typing of those various isolates could not be performed, it is possible that they were identical. This patient had not received specific preemptive antibiotics, and the bacteremia responded well to intravenous vancomycin. The other patient (patient 13) had mixed Klebsiella pneumoniae and Escherichia coli bacteremia, but only Bacillus sp had been found in the prefreezing sample. Of the remaining seven febrile patients, four patients (patients 6, 7, 10 and 12) experienced unexplained febrile neutropenia; one patient had C. difficile associated diarrhea (patient 2), one patient neutropenic colitis (patient 11) and one patient pneumonia (patient 3).
Fever after graft infusion was observed in four of the five patients who had received specific pre-emptive antibiotics, and in five of the eight patients who had not. Although this finding would suggest a lack of impact of such a strategy, the nature of the organisms was slightly different between the two groups. Indeed, six of the eight patients who did not receive specific pre-emptive antibiotics were infused with grafts contaminated with CNS; the other two patients were infused grafts contaminated with diphtheroids and Enterococcus sp. The five patients treated with specific pre-emptive antibiotics were transplanted with grafts contaminated with the following contaminants: CNS (two patients), S. viridans, Enterococcus, Bacillus and Burkholderia (one patient each). No irreversible clinical sequelae related to the infusion of contaminated grafts were observed. Two patients (patients 1 and 2) died 21 and 80 months posttransplantation, respectively, of malignant relapse.
Discussion
Despite the often numerous steps involved in the whole process of collecting and preparing hematopoietic blood products, the contamination rate of HSC grafts remains rather low. Indeed, we found that the overall rate of hematopoietic cell graft contamination was 1.0%. The fact that more than 1500 grafts were evaluated represents a sample size sufficient to provide a reasonable estimate of such rare events. Methodologically, our culture procedure is in line with that suggested for the culture of normally sterile human body fluids other than blood, urine and CSF, which closely approximates cell graft conditions. 18 Our rate of contamination may, however, be underestimated as we have used a single culture broth to determine the sterility of our grafts. In addition, increasing the volume of cell samples could increase detection of low levels of contaminants. Nevertheless, in view of the limited clinical impact of graft contamination as detected under the present low-volume conditions, it seems unlikely that attempts to enhance sensitivity through increasing the number or volumes of graft samples would have yielded clinically useful information. Indeed, our positive culture rates are strikingly similar to those reported by others using more extensive methods to assess graft sterility. 3, 4 Moreover, it may not be feasible to routinely culture greater volumes owing to the precious nature of the specimens.
Contamination is likely to occur during graft preparation and manipulation. However, we failed to identify a greater frequency of contamination in autologous grafts, which require freezing steps, than in allogeneic collections, which are usually infused fresh and require very limited handling of the graft. Interestingly, Webb et al. 4 documented that bacterial contamination tripled after monoclonal antibody purging. However, when we compared grafts that underwent purging procedures, we observed the same frequency of contamination as in our untreated grafts. It seems improbable that differences in procedures and materials would account for this discrepancy. However, it could be attributable to sample size differences, with a smaller number of treated grafts in our study compared to the Webb et al. 4 study. Nevertheless, it remains an intriguing observation and one wonders if the extensive cell washing steps at the end of the procedures could also explain the lack of increased contamination in these purged grafts. Indeed, out of the five contaminated collections that underwent laboratory manipulations (freezing or purging), only two demonstrated persistence of this organism in the final pre-freezing sample. Leakage of cryopreservation bags at the time of infusion has also been associated with contaminated grafts, and these events were sometimes catastrophic. 15, 19 Webb et al. 4 reported that 54% of 24 non-manipulated peripheral or bone marrow HSC grafts were contaminated as a result of the contact of leaking bags with unsterilized water from thawing baths. However, such events were not evaluated in the present study. Our experience and that of others show that infusion of contaminated cells rarely results in significant sequelae. 4, 5, 7, 8 Only one of our patients had a Staphylococcus epidermidis septicemia on day þ 5, which could have originated from the contaminated graft, although a catheter-related infection could not be ruled out. Despite a 2-week post-infusion monitoring period, all of the other patients infused with contaminated grafts developed severe adverse events related to the infusion, whether or not specific pre-emptive antibiotic therapies were administered. In addition, episodes of fever were not less frequent in patients receiving such specific pre-emptive antimicrobials. Despite its poor activity against skin flora contaminants, the routine use of trimethoprim-sulfamethoxazole, as bacterial prophylaxis in all of our patients, may have played a role in this favorable evolution. Interestingly, Rowley et al. 6 demonstrated that bone marrow cells possess bactericidal properties that can suppress the growth of S. epidermidis intentionally seeded into a sample, thus reducing the bacterial inoculum concentration.
Our findings and that of others 5, 6 suggest that it is likely safe to administer grafts that could be contaminated with skin contaminants during or after procurement. Refraining from giving specific pre-emptive antibiotics to patients with CNS contamination may even be acceptable.
With such low contamination rates and questionable clinical impact of positive culture results, should routine culture of stem cell products be continued? Also, how frequently should cultures be performed: at collection of cell graft, at each step of the manipulation process and before its administration? Despite the fact that these recommendations generate large numbers of sterility cultures, and add significant cost and labor to the preparation of these grafts, they fulfill the need for close quality control of the various procedures.
1,2 However, we believe that, from a clinical perspective, the final precryopreservation culture represents what the patient will be transplanted with, and is therefore the most relevant in the final decision to proceed or not with the contaminated infusion.
In conclusion, our study builds on previous reports to underline the fact that cell procurement and manipulation rarely result in contamination of cell graft products. Infusion of grafts contaminated with usual skin flora bacteria is usually without clinical consequences. In these circumstances, close monitoring may be sufficient and could avoid antibiotic-associated adverse events.
